GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Beneish M-Score

Genomic Health (FRA:G7H) Beneish M-Score : 0.00 (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Genomic Health Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Genomic Health's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Genomic Health was 0.00. The lowest was 0.00. And the median was 0.00.


Genomic Health Beneish M-Score Historical Data

The historical data trend for Genomic Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Beneish M-Score Chart

Genomic Health Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.70 -2.99 -1.70 -3.44 -2.49

Genomic Health Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.70 -2.49 -2.51 -2.90 -2.71

Competitive Comparison of Genomic Health's Beneish M-Score

For the Diagnostics & Research subindustry, Genomic Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Health's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomic Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Genomic Health's Beneish M-Score falls into.



Genomic Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Genomic Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.928+0.528 * 0.9896+0.404 * 0.885+0.892 * 1.2374+0.115 * 2.0021
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.908+4.679 * -0.069046-0.327 * 1.4067
=-2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep19) TTM:Last Year (Sep18) TTM:
Total Receivables was €50.7 Mil.
Revenue was 103.834 + 101.014 + 96.261 + 91.951 = €393.1 Mil.
Gross Profit was 86.847 + 85.372 + 81.208 + 78.159 = €331.6 Mil.
Total Current Assets was €313.3 Mil.
Total Assets was €418.1 Mil.
Property, Plant and Equipment(Net PPE) was €87.7 Mil.
Depreciation, Depletion and Amortization(DDA) was €11.7 Mil.
Selling, General, & Admin. Expense(SGA) was €225.6 Mil.
Total Current Liabilities was €52.6 Mil.
Long-Term Debt & Capital Lease Obligation was €46.1 Mil.
Net Income was 16.974 + 14.148 + 11.504 + 7.832 = €50.5 Mil.
Non Operating Income was -1.394 + -0.447 + 0.51 + -0.875 = €-2.2 Mil.
Cash Flow from Operations was 29.206 + 33.968 + -3.247 + 21.602 = €81.5 Mil.
Total Receivables was €44.2 Mil.
Revenue was 86.778 + 81.85 + 75.119 + 73.906 = €317.7 Mil.
Gross Profit was 73.479 + 69.538 + 59.926 + 62.233 = €265.2 Mil.
Total Current Assets was €211.4 Mil.
Total Assets was €257.4 Mil.
Property, Plant and Equipment(Net PPE) was €34.1 Mil.
Depreciation, Depletion and Amortization(DDA) was €10.6 Mil.
Selling, General, & Admin. Expense(SGA) was €200.8 Mil.
Total Current Liabilities was €43.2 Mil.
Long-Term Debt & Capital Lease Obligation was €0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(50.735 / 393.06) / (44.181 / 317.653)
=0.129077 / 0.139086
=0.928

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(265.176 / 317.653) / (331.586 / 393.06)
=0.834798 / 0.843601
=0.9896

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (313.293 + 87.688) / 418.053) / (1 - (211.424 + 34.112) / 257.414)
=0.040837 / 0.046144
=0.885

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=393.06 / 317.653
=1.2374

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(10.555 / (10.555 + 34.112)) / (11.735 / (11.735 + 87.688))
=0.236304 / 0.118031
=2.0021

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(225.624 / 393.06) / (200.803 / 317.653)
=0.574019 / 0.632146
=0.908

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((46.114 + 52.573) / 418.053) / ((0 + 43.197) / 257.414)
=0.236063 / 0.167811
=1.4067

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(50.458 - -2.206 - 81.529) / 418.053
=-0.069046

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Genomic Health has a M-score of -2.71 suggests that the company is unlikely to be a manipulator.


Genomic Health Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Genomic Health's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Health (FRA:G7H) Business Description

Traded in Other Exchanges
N/A
Address
301 Penobscot Drive, Redwood City, CA, USA, 94063
Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines